Heart 1997;78:426-428 ( November )
Editorial
Possible uses of gene therapy in reducing coronary restenosis
| The first 150 words of the full text of this article appear below. |
Gene transfer has been carried out in more than 700 patients as part of over 200 registered protocols in the United States and Europe since 1989. Although success rates vary and many efficacy and safety issues remain unsolved, the potential of this alternative therapeutic method is well accepted. The lack of success of many pharmaceutical agents in reducing restenosis rates after angioplasty shown in dozens of clinical trials has encouraged the development of gene therapy as a further treatment. The introduction of special catheters for local drug delivery allows high efficacy combined with maximum safety.
Pathophysiology of restenosisFour overlapping stages occur in the development of restenosis
as described in animal models. The inflammatory and thrombotic phases
begin at the time of injury and are maximal hours later. These are
followed by a proliferative phase, with the highest division activity
of smooth muscle cells about seven days after injury. Finally, there is
matrix
This article has been cited by other articles:
-
CORDEIRO, M F., SCHULTZ, G. S, ALI, R. R, BHATTACHARYA, S. S, KHAW, P. T
(1999). Molecular therapy in ocular wound healing. Br J Ophthalmol
83: 1219-1224
[Full Text]
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
